Out-of-the-Box Integration Automates Adverse Event Data Transfer Using E2B Standards to Increase Efficiency and Improve Safety Data Quality
To help clinical trial sponsors and contract research organizations (CROs) more cost-effectively and efficiently capture and manage information on adverse events, Oracle has integrated Oracle Health SciencesInForm and Oracle Argus Safety. By automating the transfer of serious adverse event (SAE) and related information from the Oracle Health Sciences InForm clinical data management system to the Oracle Argus Safety system, the integration can virtually eliminate the time, and significantly reduce the costs and potential for error associated with reformatting and rekeying data. The out-of-the-box integration, which supports both drug and medical device trials, provides a proven, robust, and configurable integration between Oracle Health Sciences InForm and Oracle Argus Safety that speeds time to deployment, virtually eliminates custom development costs, and allows managers to select how often SAE information and updates are delivered to the safety system, as well as whether the information is transmitted automatically or based on user action.
Adverse event information from Oracle Health Sciences InForm is now available to safety teams within minutes as opposed to hours or days, allowing sponsors and CROs to assess potential SAEs faster and facilitate compliance with regulatory reporting requirements. Organizations can also save valuable time at the end of an electronic data capture (EDC) trial by avoiding time-consuming reconciliations between data across the clinical data management and safety systems. This closed-loop solution is designed to improve cross-organizational communication and provides up-to-date information by returning Oracle Argus Safety case numbers and status notifications back to Oracle Health Sciences InForm.
“Out-of-the-box integration between Oracle Health Sciences InForm and Oracle Argus Safety helps trial sponsors and CROs to respond faster to potential SAEs while reducing the costs and potential for error involved in rekeying information. It also ensures consistent information between the clinical data management and safety systems, which expedites data validation at the end of a trial, ultimately accelerating time to regulatory submission,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.